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Identification Requirements for CS 
Prescriptions
A pharmacy that dispenses federally designated con-
trolled substances (CS) and Schedule VI prescription 
monitoring program (PMP) drugs (eg, gabapentin) is re-
quired to check that the photo identification (ID) matches 
the customer taking possession of the prescription, and that 
the ID is valid and not out of date.
A customer identifier is defined as the identification num-
ber on a valid government-issued ID, including state-issued 
ID, military ID cards, permanent resident cards, passports, 
driver’s licenses, Massachusetts Commission for the Blind 
ID cards, or other ID as specified by the Massachusetts 
Department of Public Health.
The pharmacy may dispense medication to the patient 
or the patient’s representative. For example, a parent may 
pick up a prescription for a child or a relative may pick 
up a prescription for a housebound family member. The 
pharmacy must check the ID of the person picking up the 
prescription.
However, there are situations when a pharmacy 
may dispense these medications without a customer’s 
identification.
If the pharmacist has reason to believe that the failure 
to dispense the medication would result in a serious hard-
ship for the patient, he or she may dispense it without 
identification if:
a. the reason is documented;
b. the patient or agent of the patient prints his or her
name and address on the reverse side of the pre-
scription and signs his or her name; or in the case
of an electronic prescription, provides an electronic
signature; and
c. the pharmacist enters “cust signed rx” in the PMP
customer ID field (AIR05) rather than leaving the
field blank.
Instructions, including a full list of acceptable customer 
identifiers, are detailed in the PMP Data Submission Guide.
MassPAT Integration Can Improve 
Pharmacy Workflow
Last June, the Massachusetts PMP presented to the Mas-
sachusetts Board of  Registration in Pharmacy an update on 
efforts to integrate the Massachusetts Prescription Aware-
ness Tool (MassPAT) directly into pharmacy software 
systems. Since then, the Massachusetts PMP has brought 
Walmart pharmacies, Boston Medical Center pharmacies, 
Cure-Aid pharmacies, and the Holyoke Health Center 
pharmacy live with the integration. The Massachusetts 
PMP is now looking to onboard additional facilities and 
will cover integration costs.
The integration fits seamlessly into the pharmacists’ 
workflow, allowing them to view a patient’s MassPAT 
prescription history directly within their pharmacy software 
system. This eliminates the need to log in to a separate 
web portal and enter the patient’s information. Instead, the 
pharmacy is able to send an automatic query to MassPAT, 
which will return the patient’s prescription information, 
viewable in the same system the pharmacist uses to fill a 
prescription.
Integration saves time and effort, and therefore it is 
not surprising that the Massachusetts PMP reports that 
patient searches have increased significantly at integrated 
pharmacies. This can only contribute to patient safety and 
better outcomes.
If your pharmacy is interested in integrating with 
MassPAT, please visit the MassPAT Electronic Health Re-
cord (EHR) Integration website and follow the steps there 
to review the MassPAT EHR Integration Welcome Packet, 
fill out the Integration Request Form, and then review and 
sign the terms and conditions.
The Massachusetts PMP is eager to work with you to 
improve pharmacist access to critical prescription history 
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trolled Substances Act. FDA approved Epidiolex for the 
treatment of seizures associated with two rare and severe 
forms of epilepsy, Lennox-Gastaut syndrome and Dravet 
syndrome, in patients two years of age and older on June 
25, 2018. Additional information is available in the an-
nouncement at www.dea.gov/press-releases/2018/09/27/
fda-approved-drug-epidiolex-placed-schedule-v-con-
trolled-substance-act. 
ASHP Guidelines Provide 
Recommendations for Preventing 
Patient Harm From Medication Errors
New guidelines from the American Society of Health-
System Pharmacists (ASHP) describe opportunities for 
pharmacists on interprofessional teams to prevent errors 
across the continuum of care in hospitals and health sys-
tems. The “ASHP Guidelines on Preventing Medication 
Errors in Hospitals” are intended to apply to the acute 
care setting because of the special collaborative processes 
established in this setting. However, these guidelines may 
be applicable to practice settings outside of the acute care 
setting, especially in health systems.
Further, the ASHP press release notes that the guide-
lines address numerous areas in the medication-use 
process where errors may occur, including: patient ad-
mission; selection and procurement; storage; ordering, 
transcribing, and reviewing; preparation; dispensing; 
administration; monitoring; evaluation; and patient 
discharge. Published in the October 1, 2018 issue of the 
American Journal of Health-System Pharmacy, the guide-
lines are available at www.ajhp.org/content/75/19/1493. 
ASHP’s October 2, 2018 press release can be found in 
the News section at www.ashp.org.
FDA’s Final Guidance Documents 
Address Compounding and 
Repackaging of Radiopharmaceuticals
On September 26, 2018, FDA published the final 
guidance titled Compounding and Repackaging of Radio-
pharmaceuticals by Outsourcing Facilities. In this final 
guidance for industry, FDA sets forth its policy regarding 
compounding and repackaging of radiopharmaceuticals 
for human use by entities that are registered with FDA as 
outsourcing facilities. This guidance describes how FDA 
generally intends to apply section 503B of the Federal 
Food, Drug, and Cosmetic Act (FD&C Act) to radio-
pharmaceuticals compounded by outsourcing facilities. 
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Final Guidance Documents Address 
FDA Policies Related to DSCSA
To help ensure that prescription drug products are 
identified and traced properly as they move through the 
supply chain in compliance with federal law, Food and 
Drug Administration (FDA) issued two final guidance 
documents related to the Drug Supply Chain Security Act 
(DSCSA). Released on September 19, 2018, the follow-
ing final guidance documents will help ensure there are 
no disruptions in the supply chain as manufacturers and 
repackagers include a product identifier on the package 
or case.
♦ Product Identifier Requirements Under the Drug
Supply Chain Security Act – Compliance Policy
addresses industry-wide readiness for implementa-
tion of the new requirements aimed at enhancing
the security of the drug supply chain. As the agency
continues to work with stakeholders to ensure proper
implementation of the law, this guidance document
specifies FDA’s one-year delay in enforcing the
manufacturers’ requirement to include a product
identifier on the package or case of products to
November 27, 2018.
♦ Grandfathering Policy for Packages and Homog-
enous Cases of Product Without a Product Identifier
outlines the circumstances in which packages and
cases of product that were in the supply chain before
the November 2018 product identifier requirement
are considered grandfathered. The grandfathering
policy describes the circumstances under which
products already in the supply chain can remain in
distribution without being relabeled with a product
identifier.
The final guidance documents can be found at www 
.fda.gov/newsevents/newsroom/fdainbrief/ucm621095 
.htm.
First FDA-Approved Drug Containing 
Extract From Cannabis Plant to Be 
Placed in Schedule V
On September 27, 2018, the United States Department 
of Justice and Drug Enforcement Administration (DEA) 
announced that Epidiolex® – which contains cannabidiol, 
a chemical constituent of the cannabis plant, and is the 
first FDA-approved drug to contain a purified extract 
from the plant – is being placed in Schedule V of  the Con-
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In addition, this guidance describes the conditions under 
which FDA generally does not intend to take action for 
violations of certain provisions of the FD&C Act when 
an outsourcing facility repackages radiopharmaceuticals, 
according to the Federal Register notice at www.gpo.gov/
fdsys/pkg/FR-2018-09-26/pdf/2018-20901.pdf. 
At the same time, FDA published the final guidance 
titled Compounding and Repackaging of Radiophar-
maceuticals by State-Licensed Nuclear Pharmacies, 
Federal Facilities, and Certain Other Entities. This 
guidance sets forth FDA’s policy regarding compound-
ing and repackaging of radiopharmaceuticals for human 
use by state-licensed nuclear pharmacies, federal facili-
ties, and other entities that hold a radioactive materials 
license for medical use issued by the Nuclear Regulatory 
Commission or by an Agreement State. Because such 
radiopharmaceuticals are not eligible for exemptions 
from provisions of the FD&C Act related to the produc-
tion of drugs, FDA is issuing this guidance to describe 
the conditions under which it generally does not intend 
to take action for violations of certain provisions of the 
FD&C Act when these entities compound or repackage 
radiopharmaceuticals. More details are available in the 
Federal Register notice at www.gpo.gov/fdsys/pkg/FR-
2018-09-26/pdf/2018-20902.pdf.
Pharmacy Toolkit Encourages 
Conversations With Patients About 
Prescription Opioids
In collaboration with its pharmacy partners and several 
state pharmacy associations, Allied Against Opioid 
Abuse (AAOA) developed a Pharmacy Toolkit to help 
pharmacists engage and educate patients about the safe 
use, storage, and disposal of pain medicines. The AAOA 
Pharmacy Toolkit includes resources to help pharmacists 
raise awareness among patients about their rights, risks, 
and responsibilities associated with prescription opioids. 
These resources include: a pharmacy display, patient 
handout, patient engagement guide, tips for talking with 
patients and caregivers, prescriber engagement guide, 
safe storage and disposal training, and social graphics. 
To learn more about the Pharmacy Toolkit and to 
obtain these resources, visit AAOA’s website at https://
againstopioidabuse.org.
Biosimilars Added to FIP’s Policy on 
Pharmacists’ Right to Substitute a 
Medication
To account for the emergence of biological medicines 
and their biosimilars onto the medical landscape, the 
International Pharmaceutical Federation (FIP) has added 
biosimilars to its policy on pharmacists’ right to substi-
tute one medicine for another. The revised Statement of 
Policy titled “Pharmacist’s authority in pharmaceutical 
product selection: therapeutic interchange and substitu-
tion” includes the core principles of  the original statement 
and the following: 
♦ generic substitution is recommended as part of the
pharmacist’s dispensing role;
♦ pharmacists should be provided with bioavailability
data by regulatory authorities and manufacturers;
and
♦ a medicine should only be substituted with a product
containing a different active ingredient in agreement
with the prescriber.
According to FIP’s October 2, 2018 press release, the 
use of generic names is still encouraged, but the revised 
statement gives focus to the use of international nonpro-
prietary names. The full Statement of Policy and press 
release are available at www.fip.org in their respective 
sections.
FDA Offers CE Course on Reducing 
Hypoglycemic Events in Patients With 
Type 2 Diabetes
FDA is offering a free, one-hour continuing educa-
tion (CE) course for health care providers (physicians, 
pharmacists, nurses, and others) about the reduction of 
hypoglycemic events in patients with Type 2 diabetes. 
The course, Leveraging Health Literacy and Patient 
Preferences to Reduce Hypoglycemic Events in Patients 
with Type 2 Diabetes, will describe the prevalence of 
hypoglycemic events and identify risk factors leading 
to an event. Available for credit through October 31, 
2020, this course will introduce methods of assessing 
health literacy and numeracy of patients and caregivers; 
review effective ways to incorporate patient prefer-
ences into care plans; and list action steps to reduce 
the likelihood of a hypoglycemic event for high-risk 
patients. To participate in this CE course, visit http://
fdapasediabetes.e-paga.com. 
The FDA Center for Drug Evaluation and Research 
(CDER) is accredited by the Accreditation Council for 
Pharmacy Education (ACPE) as a provider of continu-
ing pharmacy education (CPE). This program meets 
the criteria for one contact hour (0.1 CEU) of CPE 
credit. The ACPE Universal Activity Number for this 
knowledge-based activity is 0453-9999-17-449-H01-P. 
Further, FDA’s CDERLearn in the CDER offers a variety 
of learning opportunities, which can be found at www.fda 
.gov/Training/ForHealthProfessionals/ucm545645.htm.
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information and to combat the opioid crisis in Massachu-
setts.
Reporting the Loss of CS – Update
On December 6, 2018, the policy detailing the require-
ments for reporting a theft or loss of CS to the Board was 
updated, and a new electronic fillable loss reporting form 
was instituted.
The updated policy requires pharmacies to email the 
Board within seven business days of the discovery of a 
possible significant loss.
Within the next 21 days, or upon completion of in-
vestigation, whichever comes first, the pharmacy must 
then report to the Board the findings of its investigation. 
Regardless of the outcome of the investigation, the 
pharmacy must submit the outcome of its investiga-
tion in accordance with the requirements defined in 
Board Policy 2018-05.
If it is determined that a significant loss did not occur, 
the pharmacy must report back to the Board with a detailed 
description of the investigatory process that concluded no 
reportable loss occurred.
If the investigation confirms a significant loss, the 
report must be submitted within seven business days of 
confirming a significant loss.
The policy includes updated descriptions for types of 
losses, including those that are considered “not report-
able.” Non-reportable losses include insignificant losses 
and losses resulting from confirmed dispensing errors.
Common errors in reporting include untimely and in-
complete submissions (eg, an incomplete reporting form 
or missing documentation requirements from Appendix I).
The reporting form must be completed electronically, 
and then emailed to dhpl-opp.admin@massmail.state 
.ma.us.
Getting to Know the Board Staff
This quarter, we are highlighting Board staff member 
Ed Taglieri, MSM, NHA, RPh. Ed is the current phar-
macy substance use disorder (PSUD) program supervisor.
Ed graduated from Massachusetts College of  Pharmacy 
and Health Sciences with a bachelor of science degree in 
pharmacy in 1982. Shortly after graduation, he discovered 
that he had a very strong interest in health care manage-
ment. This encouraged him to start his own business, a 
home health care agency called Health Force, to which he 
dedicated the next twenty years of his career.
In 2013, Ed was chosen to be a Board member and he 
filled the long-term care pharmacist seat on the Board. He 
served as president during his fourth year on the Board and 
remained a Board member until early August 2017.
During his fifth and final year on the Board, the newly 
instituted position of PSUD program supervisor became 
available, which caught Ed’s attention. “It was a combina-
tion of my entire career, as I encountered cases of employ-
ees diverting medications due to substance use disorders in 
my previous jobs,” Ed explained. He began working full-
time as the PSUD program supervisor in late August 2017.
Ed enjoys the diversity of  this job, in that he is able to be 
involved with many other initiatives within the Board. He 
has said that he simply enjoys “helping people once they 
decide they are ready to be helped.” When asked about why 
he wanted to be involved in PSUD, Ed responded, “I am 
entering the last phase of my career, and I would like to give 
back before finishing my career as a pharmacist. Students 
come out of pharmacy school and their first goal, as was 
mine, is to help people, but sometimes that goal is lost along 
the way. I want to exit my career with the same mindset I 
came into it: to help people and make a difference.”
Did You Know?
 ♦ Board meetings are open to the public and held at 239 
Causeway Street, 4th Floor, Room 417, beginning at 
8:30 am on the first Thursday of  the month. The schedule 
for the 2019 Board meetings can be found here.
 ♦ Massachusetts lawmakers recently passed legislation 
mandating electronic prescribing for all Schedule II-VI 
drugs, effective January 1, 2020. Stay tuned for more 
information!
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David Sencabaugh, RPh.......................Executive Director
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Joanne Trifone, RPh......Director of  Pharmacy Investigations
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